Full-Time

Senior Principal Computational Biologist

Computational Biology

Posted on 9/4/2025

Cellarity

Cellarity

51-200 employees

Cellular-targeted drug discovery using AI

Compensation Overview

$140k - $206k/yr

+ Annual Incentive Program

Cambridge, MA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Python
Machine Learning
Data Analysis
Requirements
  • Ph.D. or equivalent in biology, computational biology, or related scientific field.
  • 4+ years of relevant industry experience.
  • Extensive experience in analyzing and deriving hypothesis from single-cell transcriptomic data, preferably also with large-scale single-cell atlases.
  • Demonstrated scientific understanding of molecular and systems biology, diverse molecular data types, and analysis tools.
  • Practical programming and scripting skills, preferably in Python.
  • Fast learner, analytical thinker, creative, "hands-on", strong communication skills.
  • Able to work both independently and as part of a team.
Responsibilities
  • Apply computational biology and machine learning tools to generate insights and hypotheses from high-dimensional molecular datasets, with a focus on large-scale scRNA-seq & snRNA-seq disease atlases.
  • Develop & lead data analysis strategies and ideation across diverse biological and clinically relevant projects with internal and external stakeholders.
  • Act as the computational biology co-lead on drug programs, working with experimental scientists to ensure that study designs & data are properly interrogated to deliver high value readouts.
  • Present your results in an interdisciplinary team of biologists, chemists, clinicians, technologists, and other machine learning colleagues in meetings covering cross-functional project teams, functional teams, to whole company and management meetings.
Desired Qualifications
  • Background in metabolic or liver diseases, autoimmune disease, or hematology.
  • Experience with generating, analyzing, and deriving hypotheses from other single-cell omics data types or large-scale clinical datasets.
  • Experience driving an impactful and relevant project within industry.
  • Background in statistics or machine learning.
  • Experience with clinical or biological data.
  • Interested in learning any of the above.

Cellarity develops drugs by looking at whole-cell biology rather than single molecular targets. Its platform uses genomics, systems biology, data science, and AI to map cellular dysfunction and uncover new biology that can treat diseases. Their drug discovery process starts from understanding disease biology, identifying how cells malfunction, and then creating therapies that address those cellular changes. This approach aims to generate medicines for complex and often overlooked diseases, with programs in hematology, immuno-oncology, and metabolism, and then bring these therapies to hospitals and clinics. Compared with traditional pharma, Cellarity emphasizes a holistic cellular view and data-driven insights to discover drug candidates more efficiently. The company's goal is to deliver a new generation of medicines that offer more effective treatments for a wide range of diseases.

Company Size

51-200

Company Stage

Series C

Total Funding

$294M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Novo Nordisk $532M MASH collaboration validates platform and funds pipeline expansion.
  • ASH 2025 oral presentations showcase CLY-124 and myelofibrosis data leadership.
  • Woelk's VP Platform appointment scales AI models across hematology and immunology.

What critics are saying

  • CLY-124 Phase 1 fails in 12-24 months, eliminating sole clinical asset.
  • Novo terminates MASH deal in 18-30 months if preclinical data underperforms.
  • Flagship deprioritizes Cellarity in 12-18 months, drying funding sources.

What makes Cellarity unique

  • Cellarity targets entire cell states using multi-omics and AI, unlike single-target traditional methods.
  • CLY-124 employs novel globin-switching mechanism for sickle cell disease in Phase 1 trial.
  • JAK2V617F-selective inhibitors for myelofibrosis derived from single-cell RNA sequencing maps.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-4%

2 year growth

0%
BioSpace
Nov 4th, 2025
Cellarity Announces Two Oral Presentations During the 67th American Society of Hematology Annual Meeting

Cellarity announces two oral presentations during the 67th American Society of Hematology Annual Meeting. * Oral Presentation during the emerging targets session on CLY-124, a clinical stage, first-in-class DCN1 inhibitor designed for sickle cell disease * Second oral presentation during the novel therapeutics session illustrating Cellarity's approach to selectively targeting JAK2V617F in patients with myelofibrosis SOMERVILLE, Mass.-(BUSINESS WIRE)-Cellarity, a clinical-stage, biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced acceptance of two oral presentations on its sickle cell disease (SCD) and myelofibrosis programs during the 67th American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 in Orlando, Florida. "Cellarity's approach to discovering and developing transformational therapies applies an advanced transcriptomics and AI-powered platform to discover, characterize and target cellular pathways that contribute to disease. The data we're presenting at ASH this year illustrate the profound potential for impact of this approach in sickle cell disease and myelofibrosis - two challenging diseases with high unmet medical need," said Cameron Trenor, M.D., Chief Medical Officer of Cellarity. "We are excited to unveil differentiating data for our lead asset, CLY-124, which is currently under evaluation in a Phase 1 trial, as well as emerging insights on novel, highly selective small molecules designed with disease modifying potential to reverse JAK2-aberrant cell behavior that drives myelofibrosis." Oral Presentation Details Oral Presentation: Identification of small molecules that selectively target JAK2V617F driven cytokine-independent megakaryopoiesis by leveraging single cell RNA sequencing maps of myelofibrosis patient samples and a deep learning framework (Pub 389) Session 802: Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies? Time and location: December 6, 5:00 - 5:15 PM, OCCC - W331 About Cellarity Founded by Flagship Pioneering in 2019, Cellarity is pioneering a fundamentally new approach to drug discovery that corrects whole cell-state dysfunction to solve complex diseases. The Company's proprietary drug discovery platform leverages advanced transcriptomics to comprehensively understand gene networks and applies the power of dynamic AI modeling to predict and design oral Cell State-Correcting therapeutics that can precisely regulate genetic switch mechanisms to restore proper cell function. The Company's lead asset, CLY-124, is designed to treat sickle cell disease through a novel globin-switching mechanism and is under evaluation in a Phase 1 clinical study. Additional candidates designed by the platform are advancing for indications in hematology and immunology, and Cellarity has an active collaboration with Novo Nordisk targeting metabolic dysfunction-associated steatohepatitis (MASH). For more information visit www.cellarity.com.

CEOWORLD Magazine
Jan 21st, 2025
Pharming Group Nominates Fabrice Chouraqui as New CEO and Executive Director

Pharming confirmed that Chouraqui will resign from his position as Executive Chairman of Cellarity, Inc. before assuming his new role as CEO.

Haymarket Media
May 9th, 2024
The Escalator: Pfizer, GSK, The 4A's and more

VantAI named John Cuozzo, a former exec at Relay Therapeutics, as SVP, head of drug discovery.

Business Wire
May 7th, 2024
Cellarity Appoints Head Of Platform To Advance Vision For Novel Drug Creation

SOMERVILLE, Mass.--(BUSINESS WIRE)--Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, today announced the appointment of Christopher (“Topher”) Woelk, Ph.D., as Vice President and Head of Platform. In this role, Woelk will lead Cellarity’s revolutionary platform to create drugs that are presently out of reach with traditional methods of drug discovery. The Cellarity platform uses proprietary AI models to link biology and chemistry with high-dimensional multi-omic data to uncover novel actionable insights into disease biology and create non-intuitive drug candidates in a vast array of clinical conditions. The platform has already produced foundational programs in several disease areas, including sickle cell disease (SCD) and metabolic dysfunction-associated steatohepatitis (MASH, in collaboration with Novo Nordisk). “We are at a pivotal moment in our journey at Cellarity as our first drug candidate in sickle cell disease moves to IND enabling studies,” said Fabrice Chouraqui, Pharm.D., CEO of Cellarity and a CEO-Partner at Flagship Pioneering. “Topher’s experience is particularly relevant to Cellarity as we continue to invest in our platform

Labiotech.eu
Mar 12th, 2024
The Twelve Hottest Biotech Companies In The Boston Area

The Boston region in the U.S. state of Massachusetts (MA) hosts one of the leading biotech hubs in the world, ranking second just in front of the BioHealth Capital Region. Here are twelve of Boston’s most innovative biotech companies.The Boston region has sprouted many influential public biotech companies. One of the most successful in recent years was Moderna, a giant messenger RNA (mRNA) specialist incubated by the VC firm Flagship Pioneering. Moderna would go on to produce one of the first COVID-19 vaccines in 2020. Another prestigious name, Vertex Pharmaceuticals, one of the 14 biotechs with a market capitalization above $100 billion, is also headquartered in Boston.The Boston hub shows few signs of slowing down, and there is a host of biotech companies generating excitement among investors.Table of contentsAkouosAkouos, founded in 2016 focuses on developing gene therapies for hearing loss

INACTIVE